Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a CBD cream soothe Eczema's relentless itch?

NCT ID NCT06994520

Disease control Sponsor: Khon Kaen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether a 5% cannabidiol (CBD) cream can reduce itching and skin severity in adults with chronic eczema conditions like atopic dermatitis and nummular eczema. About 60 participants will apply the CBD cream or a standard steroid cream for 4 weeks. The study measures changes in itch intensity and skin signs like redness and scaling, aiming to see if CBD offers a safer long-term option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a 5% cannabidiol (CBD) cream
What this could lead to
If effective, this could offer a new, non-steroid option for managing chronic eczema itch and skin inflammation.
What could go wrong
This is a small, early-stage trial, so results may not apply broadly. CBD creams can cause skin irritation, and the effect may be no better than standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. All participants must be aged 25 years or older. 2. Patients must be diagnosed with eczema, including atopic dermatitis, nummular eczema, lichen simplex chronicus, or prurigo nodularis, with pruritus persisting for more than 6 weeks. 3. Patients must be willing to refrain from using other topical products throughout the 4-week study period. 4. Patients must provide written informed consent to participate in the study. Exclusion Criteria: 1. Patients who have taken oral steroids, immunosuppressive drugs, or received phototherapy within the past 3 months. 2. Patients with chronic kidney disease, liver cirrhosis, cancer, or thyroid disease. 3. Pregnant or breastfeeding women, or women planning to become pregnant. 4. Patients who develop erythematous itchy rash in response to an open patch test using cannabis extract products. 5. Patients with a known allergy to cannabis-derived products, which may result from other ingredients and/or solvents used in the extraction process. 6. Patients with severe or unstable cardio-pulmonary diseases (e.g., angina, peripheral vascular disease, cerebrovascular disease, or arrhythmia), or those at risk of cardiovascular disease. 7. Patients with a history of psychosis, current active mood disorder, or anxiety disorder. 8. Patients who are addicted to substances, including nicotine, or are heavy alcohol users. 9. Patients using other medications, particularly opioids or sedatives such as benzodiazepines. 10. Patients taking medications known to potentially interact with cannabis extracts, such as warfarin, fluoroquinolones, or dihydropyridine calcium channel blockers.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema neurodermatitis prurigo nodularis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis Chronic pruritus Eczema Nummular eczema Prurigo nodularis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Khon Kaen University

    Khon Kaen, Changwat Khon Kaen, 40002, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.